Background Idiopathic pulmonary fibrosis (IPF) is a progressive disease of lung parenchymal scarring that is triggered by ...

Treatment practices in the U.S. show approximately 75% of diagnosed pulmonary sarcoidosis patients require treatment with ...

characterised by excessive fibrotic tissue deposition in the pulmonary parenchyma. The term "pulmonary" refers to the lungs, while "fibrosis" denotes pathological scarring. The disease disrupts ...

In COPD, the lung may express even greater variability, since the airways may be affected even more than the parenchyma. Emphysema is patchy at the same time, while the airways and local areas in ...

Imatinib is under clinical development by Aerami Therapeutics and currently in Phase I for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease). According to GlobalData, Phase I drugs for ...

Interstitial lung disease (ILD) causes significant morbidity and mortality in patients with systemic autoimmune rheumatic diseases. Patients at high risk of ILD should be screened using high ...

This perspective will provide an overview of selected parenchymal lung diseases and emphasize the complexity of assessing biomarkers from the point of the lung pathology, different types of ...

There are two kinds of lung structures: parenchymal and non-parenchymal. Pulmonary (lung) embolism is the most frequent pulmonary manifestation in APS. The frequency varies between studies, ranging ...

with effusions vasculitis pulmonary hypertension ILDs are types of pulmonary parenchymal disease. This means they affect the area around the lungs’ air sacs. Vasculitis and pulmonary ...

Conclusion: Ground glass opacities, reticulations, and consolidation are fairly common in patients with pulmonary sequelae of COVID-19. It has a peculiar predilection for involvement of subpleural ...

The new method developed by KAUST—known as Deep-Lung Parenchyma-Enhancing (DLPE)—overlays artificial intelligence algorithms on top of standard chest imaging data to reveal otherwise ...